본문 바로가기
KERD
논문KCI 등재

The management of post-transplantation recurrence of hepatocellular carcinoma

Luckshi Rajendran|Tommy Ivanics|Marco PAW Claasen|Hala Muaddi|Gonzalo Sapisochin
대한간학회 (The korean Association for the Study of the Liver)|2022.01|Clinical and Molecular Hepatology|제28권 제1호|pp. 1-16|DOI 10.3350/cmh.2021.0217

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Disease managementHepatocellular carcinomaRecurrenceImmunosuppressionLiver transplant

초록

The annual incidence of hepatocellular carcinoma (HCC) continues to rise. Over the last two decades, liver transplantation (LT) has become the preferable treatment of HCC, when feasible and strict selection criteria are met. With the rise in HCC-related LT, compounded by downstaging techniques and expansion of transplant selection criteria, a parallel increase in number of post-transplantation HCC recurrence is expected. Additionally, in the context of an immunosuppressed transplant host, recurrences may behave aggressively and more challenging to manage, resulting in poor prognosis. Despite this, no consensus or best practice guidelines for post-transplantation cancer surveillance and recurrence management for HCC currently exist. Studies with adequate population sizes and high-level evidence are lacking, and the role of systemic and locoregional therapies for graft and extrahepatic recurrences remains under debate. This review seeks to summarize the existing literature on post-transplant HCC surveillance and recurrence management. It highlights the value of early tumour detection, re-evaluating the immunosuppression regimen, and staging to differentiate disseminated recurrence from intrahepatic or extrahepatic oligo-recurrence. This ultimately guides decision-making and maximizes treatment effect. Treatment recommendations specific to recurrence type are provided based on currently available locoregional and systemic therapies.

Abstract

The annual incidence of hepatocellular carcinoma (HCC) continues to rise. Over the last two decades, liver transplantation (LT) has become the preferable treatment of HCC, when feasible and strict selection criteria are met. With the rise in HCC-related LT, compounded by downstaging techniques and expansion of transplant selection criteria, a parallel increase in number of post-transplantation HCC recurrence is expected. Additionally, in the context of an immunosuppressed transplant host, recurrences may behave aggressively and more challenging to manage, resulting in poor prognosis. Despite this, no consensus or best practice guidelines for post-transplantation cancer surveillance and recurrence management for HCC currently exist. Studies with adequate population sizes and high-level evidence are lacking, and the role of systemic and locoregional therapies for graft and extrahepatic recurrences remains under debate. This review seeks to summarize the existing literature on post-transplant HCC surveillance and recurrence management. It highlights the value of early tumour detection, re-evaluating the immunosuppression regimen, and staging to differentiate disseminated recurrence from intrahepatic or extrahepatic oligo-recurrence. This ultimately guides decision-making and maximizes treatment effect. Treatment recommendations specific to recurrence type are provided based on currently available locoregional and systemic therapies.

참고문헌 (134)

  1. Sung H, "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 71, pp.209~249 (2021)
  2. Altekruse SF, "Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005", J Clin Oncolr, 27, pp.1485~1491 (2009)
  3. Global Burden of Disease Cancer Collaboration, "Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015 : a systematic analysis for the global burden of disease study", JAMA Oncol, 3, pp.524~548 (2017)
  4. Scortegagna E Jr, "Hepatocellular carcinoma recurrence pattern following liver transplantation and a suggested surveillance algorithm", Clin Imaging, 40, pp.1131~1134 (2016)
  5. Yang JD, "Hepatocellular carcinoma is the most common indication for liver transplantation and placement on the waitlist in the United States", Clin Gastroenterol Hepatol, 15, pp.767~775 (2017)
  6. Berenguer M, "Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working group report from the ILTS transplant oncology consensus conference", Transplantation, 104, pp.1143~1149 (2020)
  7. Silva M, "Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma", Liver Transpl, 14, pp.1449~1460 (2008)
  8. Sapisochin G, "Liver transplantation for hepatocellular carcinoma : outcomes and novel surgical approaches", Nat Rev Gastroenterol Hepatol, 14, pp.203~217 (2017)
  9. Ivanics T, "Trends in indications and outcomes of liver transplantation in Canada : a multicenter retrospective study", Transpl Int, 34, pp.1444~1454 (2021)
  10. Bodzin AS, "Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation : impact of treatment modality and recurrence characteristics", Ann Surg, 266, pp.118~125 (2017)
  11. Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
  12. Clavien PA, "Recommendations for liver transplantation for hepatocellular carcinoma : an international consensus conference report", Lancet Oncol, 13, pp.e11~e22 (2012)
  13. Lingiah VA, "Liver transplantation beyond Milan criteria", J Clin Transl Hepatol, 8, pp.69~75 (2020)
  14. Mazzaferro V, "Liver transplantation in hepatocellular carcinoma after tumour downstaging(XXL) : a randomised, controlled, phase 2b", 3trial, 2020, pp.21, 947~956
  15. Lerut J, "Hepatocellular cancer selection systems and liver transplantation : from the tower of babel to an ideal comprehensive score", Updates Surg, 73, pp.1599~1614 (2021)
  16. Roh YN, "The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation", Clin Transplant, 28, pp.141~148 (2014)
  17. Sapisochin G, "Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series", Ann Surg Oncol, 22, pp.2286~2294 (2015)
  18. Victor DW 3rd, "Outcomes of liver transplantation for hepatocellular carcinoma beyond the University of California San Francisco criteria : a single-center experience", Transplantation, 104, pp.113~121 (2020)
  19. Escartin A, "Recurrence of hepatocellular carcinoma after liver transplantation", Transplant Proc, 39, pp.2308~2310 (2007)
  20. Hoffman D, "Recurrence of hepatocellular carcinoma following liver transplantation", Expert Rev Gastroenterol Hepatol, 15, pp.91~102 (2021)
  21. Rubin J, "Management of recurrent hepatocellular carcinoma in liver transplant recipients : a systematic review", Exp Clin Transplant, 10, pp.531~543 (2012)
  22. Lee DD, "Surveillance for HCC after liver transplantation : increased monitoring may yield aggressive treatment options and improved postrecurrence survival", Transplantation, 104, pp.2105~2112 (2020)
  23. Valdivieso A, "Management of hepatocellular carcinoma recurrence after liver transplantation", Transplant Proc, 42, pp.660~662 (2010)
  24. Mehta N, "Validation of a risk estimation of tumor recurrence after transplant(RETREAT)score for hepatocellular carcinoma recurrence after liver transplant", JAMA Oncol, 3, pp.493~500 (2017)
  25. Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
  26. Claasen MPAW, "Prognostic risk scores for liver transplantation : game changers or statistical artworks?", Hepatobiliary Surg Nutr, 10, pp.553~557 (2021)
  27. de’Angelis N, "Managements of recurrent hepatocellular carcinoma after liver transplantation : a systematic review", World J Gastroenterol, 21, pp.11185~11198 (2015)
  28. Lucey MR, "Long-term management of the successful adult liver transplant : 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation", Liver Transpl, 19, pp.3~26 (2013)
  29. Verna EC, "Liver transplantation for hepatocellular carcinoma : management after the transplant", Am J Transplant, 20, pp.333~347 (2020)
  30. Foerster F, "Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre", United European Gastroenterol J, 7, pp.838~849 (2019)
  31. Chagas AL, "Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study : clinical profile and prognostic factors of survival", Eur J Gastroenterol Hepatol, 31, pp.1148~1156 (2019)
  32. Osho A, "Role of imaging in management of hepatocellular carcinoma : surveillance, diagnosis, and treatment response", Hepatoma Res, 6, pp.55~ (2020)
  33. Alshahrani AA, "Clinical features and surveillance of very late hepatocellular carcinoma recurrence after liver transplantation", Ann Transplant, 23, pp.659~665 (2018)
  34. Al-Ameri AAM, "Systematic review : risk prediction models for recurrence of hepatocellular carcinoma after liver transplantation", Transpl Int, 33, pp.697~712 (2020)
  35. Minjeong Kim, "Risk factors for poor survival after recurrence of hepatocellular carcinoma after liver transplantation", Annals of Surgical Treatment and Research, 101(1), pp.28~36 (2021), 대한외과학회
  36. von Felden J, "Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma", Liver Transpl, 26, pp.823~831 (2020)
  37. Ho CM, "Survival after treatable hepatocellular carcinoma recurrence in liver recipients : a nationwide cohort analysis", Front Oncol, 10, pp.616094~ (2020)
  38. Li BCW, "The outcomes of systemic treatment in recurrent hepatocellular carcinomas following liver transplants", Adv Ther, 38, pp.3900~3910 (2021)
  39. Chok KS, "Late recurrence of hepatocellular carcinoma after liver transplantation", World J Surg, 35, pp.2058~2062 (2011)
  40. Aggarwal A, "A national survey of hepatocellular carcinoma surveillance practices following liver transplantation", Transplant Direct, 7, pp.e638~ (2021)
  41. Liu D, "Evidence-based surveillance imaging schedule after liver transplantation for hepatocellular carcinoma recurrence", Transplantation, 101, pp.107~111 (2017)
  42. Ladabaum U, "Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation", Clin Transplant, 25, pp.283~291 (2011)
  43. Hwang S, "Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation", Transplant Proc, 45, pp.3076~3384 (2013)
  44. 박민수, "Optimal Tailored Screening Protocol after Living Donor Liver Transplantation for Hepatocellular Carcinoma", Journal of Korean Medical Science, 29(10), pp.1360~1366 (2014), 대한의학회
  45. Ruggiero RA, ""Concomitant immunity"in murine tumours of non-detectable immunogenicity", Br J Cancer, 51, pp.37~48 (1985)
  46. Janssen LME, "The immune system in cancer metastasis : friend or foe?", J Immunother Cancer, 5, pp.79~ (2017)
  47. Au KP, "Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma : a proposed management algorithm", World J Gastroenterol, 24, pp.5081~5094 (2018)
  48. Rodríguez-Perálvarez M, "Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma", J Hepatol, 59, pp.1193~1199 (2013)
  49. Vivarelli M, "Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors : reassessment of risk factors for tumor recurrence", Ann Surg, 248, pp.857~862 (2008)
  50. Vivarelli M, "Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma : key role of immunosuppression", Liver Transpl, 11, pp.497~503 (2005)
  51. Regalia E, "Pattern and management of recurrent hepatocellular carcinoma after liver transplantation", J Hepatobiliary Pancreat Surg, 5, pp.29~34 (1998)
  52. Zavaglia C, "Predictors of long-term survival after liver transplantation for hepatocellular carcinoma", Am J Gastroenterol, 100, pp.2708~2716 (2005)
  53. Faivre S, "Current development of mTOR inhibitors as anticancer agents", Nat Rev Drug Discov, 5, pp.671~688 (2006)
  54. Matter MS, "Targeting the mTOR pathway in hepatocellular carcinoma : current state and future trends", J Hepatol, 60, pp.855~865 (2014)
  55. Zhou L, "The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma", Med Oncol, 27, pp.255~261 (2010)
  56. Guba M, "Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis : involvement of vascular endothelial growth factor", Nat Med, 8, pp.128~135 (2002)
  57. Sehgal SN, "Rapamune(RAPA, rapamycin, sirolimus) : mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression", Clin Biochem, 31, pp.335~340 (1998)
  58. Au KP, "Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence : is it too late?", World J Gastrointest Surg, 12, pp.149~158 (2020)
  59. Toso C, "Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma", Hepatology, 51, pp.1237~1243 (2010)
  60. Yang Z, "Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation : preliminary experience", Hepatobiliary Pancreat Dis Int, 19, pp.365~370 (2020)
  61. Geissler EK, "Sirolimus use in liver transplant recipients with hepatocellular carcinoma : a randomized, multicenter, open-label phase 3 trial", Transplantation, 100, pp.116~125 (2016)
  62. Akhan O, "Irreversible electroporation of recurrent hepatocellular carcinoma after liver transplantation : report of two cases", Cardiovasc Intervent Radiol, 44, pp.807~811 (2021)
  63. Fernandez-Sevilla E, "Recurrence of hepatocellular carcinoma after liver transplantation : is there a place for resection?", Liver Transpl, 23, pp.440~447 (2017)
  64. Roayaie S, "Recurrence of hepatocellular carcinoma after liver transplant : patterns and prognosis", Liver Transpl, 10, pp.534~540 (2004)
  65. Sommacale D, "Liver resection in transplanted patients : a single-center Western experience", Transplant Proc, 45, pp.2726~2728 (2013)
  66. Chok KSH, "Management of recurrent hepatocellular carcinoma after liver transplant", World J Hepatol, 7, pp.1142~1148 (2015)
  67. Huang J, "Is radiofrequency ablation applicable for recurrent hepatocellular carcinoma after liver transplantation?", J Surg Res, 200, pp.122~130 (2016)
  68. Marangoni G, "Liver resection in liver transplant recipients", Hepatobiliary Pancreat Dis Int, 7, pp.590~594 (2008)
  69. Kneuertz PJ, "Multidisciplinary management of recurrent hepatocellular carcinoma following liver transplantation", J Gastrointest Surg, 16, pp.874~881 (2012)
  70. Kornberg A, "Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients : clinical patterns and outcome variables", Eur J Surg Oncol, 36, pp.275~280 (2010)
  71. Arii S, "Results of surgical treatment for recurrent hepatocellular carcinoma;comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence", J Hepatobiliary Pancreat Surg, 5, pp.86~92 (1998)
  72. Minagawa M, "Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma", Ann Surg, 238, pp.703~710 (2003)
  73. Shimada M, "Prognosis of recurrent hepatocellular carcinoma : a 10-year surgical experience in Japan", Gastroenterology, 111, pp.720~726 (1996)
  74. Guo R, "Short-and longterm outcomes of hepatectomy with or without radiofrequencyassist for the treatment of hepatocellular carcinomas : a retrospective comparative cohort study", Biosci Trends, 9, pp.65~72 (2015)
  75. Huang J, "Radiofrequency ablation versus surgical resection for hepatocellular carcinoma in Childs A cirrhotics-a retrospective study of 1, 061 cases", J Gastrointest Surg, 15, pp.311~320 (2011)
  76. Chen MS, "A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma", Ann Surg, 243, pp.321~328 (2006)
  77. Zhai H, "Microwave ablation in treating intrahepatic recurrence of hepatocellular carcinoma after liver transplantation : an analysis of 11 cases", Int J Hyperthermia, 31, pp.863~868 (2015)
  78. Sanuki N, "Role of stereotactic body radiation therapy for hepatocellular carcinoma", World J Gastroenterol, 20, pp.3100~3111 (2014)
  79. Gupta A, "Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation", J Immunol, 189, pp.558~566 (2012)
  80. Sharabi AB, "Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen", Cancer Immunol Res, 3, pp.345~355 (2015)
  81. Bujold A, "Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma", J Clin Oncol, 31, pp.1631~1639 (2013)
  82. Andolino DL, "Stereotactic body radiotherapy for primary hepatocellular carcinoma", Int J Radiat Oncol Biol Phys, 81, pp.e447~e453 (2011)
  83. Cárdenes HR, "Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma", Clin Transl Oncol, 12, pp.218~225 (2010)
  84. Eriguchi T, "Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma : systematic review and meta-analysis of propensity score studies", Hepatol Res, 51, pp.813~822 (2021)
  85. Au KP, "Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation", World J Clin Cases, 8, pp.2758~2768 (2020)
  86. Zhou B, "Chemoembolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation", J Vasc Interv Radiol, 21, pp.333~338 (2010)
  87. 고흥규, "Tumor Response to Transcatheter Arterial Chemoembolization in Recurrent Hepatocellular Carcinoma after Living Donor Liver Transplantation", Korean Journal of Radiology, 8(4), pp.320~327 (2007), 대한영상의학회
  88. Salem R, "Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres : a comprehensive report of long-term outcomes", Gastroenterology, 138, pp.52~64 (2010)
  89. Lee S, "Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma : comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study", Acta Radiol, 58, pp.131~139 (2017)
  90. Pollock RF, "A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials", Expert Rev Anticancer Ther, 21, pp.341~349 (2021)
  91. Tomimaru Y, "The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma", Am J Surg, 192, pp.46~51 (2006)
  92. Jeong YH, "Surgical outcome of pulmonary metastasectomy for hepatocellular carcinoma recurrence in liver transplant patients", Ann Transplant, 26, pp.e930383~ (2021)
  93. Hwang S, "Resection of pulmonary metastases from hepatocellular carcinoma following liver transplantation", World J Surg, 36, pp.1592~1602 (2012)
  94. Hu JG, "En bloc lumpectomy of T12 vertebra for progressive hepatocellular carcinoma metastases following liver transplantation:a case report", Medicine(Baltimore), 99, pp.e18756~ (2020)
  95. Abdel Wahab M, "Adrenalectomy for solitary recurrent hepatocellular carcinoma five years after living donor liver transplantation : a case report", Int J Surg Case Rep, 54, pp.23~27 (2019)
  96. Jalbani IK, "Adrenalectomy for solitary metastasis of hepatocellular carcinoma post liver transplantation : case report and literature review", Pak J Med Sci, 32, pp.1044~1046 (2016)
  97. Ikegami T, "Surgical resection for lymph node metastasis after liver transplantation for hepatocellular carcinoma", Anticancer Res, 37, pp.891~895 (2017)
  98. Aoki M, "Stereotactic body radiotherapy for lung metastases as oligorecurrence : a single institutional study", J Radiat Res, 57, pp.55~61 (2016)
  99. Walburn T, "Stereotactic body radiation therapy for recurrent, isolated hepatocellular carcinoma lymph node metastasis with or without prior liver transplantation", Cureus, 12, pp.e9988~ (2020)
  100. Llovet JM, "Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma", Nat Rev Gastroenterol Hepatol, 18, pp.293~313 (2021)
  101. Xu X, "Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China(2018 edition)", Hepatobiliary Pancreat Dis Int, 18, pp.307~312 (2019)
  102. Faivre S, "Molecular therapies for HCC : Looking outside the box", J Hepatol, 72, pp.342~352 (2020)
  103. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
  104. de’Angelis N, "Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation", Prog Transplant, 26, pp.348~355 (2016)
  105. Mancuso A, "Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation : a systematic review and meta-analysis", Dig Liver Dis, 47, pp.324~330 (2015)
  106. Sposito C, "Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation : a case-control study", J Hepatol, 59, pp.59~66 (2013)
  107. Zavaglia C, "Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation : experience at a single center and review of the literature", Eur J Gastroenterol Hepatol, 25, pp.180~186 (2013)
  108. Sotiropoulos GC, "Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation", Transplant Proc, 44, pp.2754~2756 (2012)
  109. Vitale A, "Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?", Transplant Proc, 44, pp.1989~1991 (2012)
  110. Weinmann A, "Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation", Dig Liver Dis, 44, pp.432~437 (2012)
  111. Yoon DH, "Sorafenib for recurrent hepatocellular carcinoma after liver transplantation", Jpn J Clin Oncol, 40, pp.768~773 (2010)
  112. Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, doubleblind, placebo-controlled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
  113. Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 noninferiority trial", Lancet, 391, pp.1163~1173 (2018)
  114. Iavarone M, "Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation", Am J Transplant, 19, pp.3176~3184 (2019)
  115. Couzin-Frankel J, "Immune therapy steps up the attack", Science, 330, pp.440~443 (2010)
  116. El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
  117. Zhu AX, "Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224) : a nonrandomised, open-label phase 2 trial", Lancet Oncol, 19, pp.940~952 (2018)
  118. Finn RS, "Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma", N Engl J Med, 382, pp.1894~1905 (2020)
  119. Finkelmeier F, "Nivolumab for the treatment of hepatocellular carcinoma", Expert Rev Anticancer Ther, 18, pp.1169~1175 (2018)
  120. Amjad W, "Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab", J Clin Exp Hepatol, 10, pp.185~187 (2020)
  121. DeLeon TT, "Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation : the Mayo Clinic experience", J Gastrointest Oncol, 9, pp.1054~1062 (2018)
  122. De Toni EN, "Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient", Gastroenterology, 152, pp.1631~1633 (2017)
  123. Friend BD, "Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma", Pediatr Blood Cancer, 64, pp.e26682~ (2017)
  124. Varkaris A, "Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma", Am J Gastroenterol, 112, pp.1895~1896 (2017)
  125. Sanduzzi-Zamparelli M, "New systemic treatments in advanced hepatocellular carcinoma", Liver Transpl, 25, pp.311~322 (2019)
  126. "Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation"[URL]
  127. "Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant"[URL]
  128. "Cabozantinib to Treat Recurrent Liver Cancer Post Transplant"[URL]
  129. "Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver Transplantation (RRHCCLT)"[URL]
  130. "TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation"[URL]
  131. "A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation"[URL]
  132. Duvoux C, "Liver transplantation for hepatocellular carcinoma : a model including α-fetoprotein improves the performance of Milan criteria", Gastroenterology, 143, pp.986~994 (2012)
  133. Lai Q, "A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation : time-radiologicalresponse-alpha-fetoprotein-INflammation(TRAIN)score", Ann Surg, 264, pp.787~796 (2016)
  134. Halazun KJ, "Recurrence after liver transplantation for hepatocellular carcinoma : a new MORAL to the story", Ann Surg, 265, pp.557~564 (2017)

관련 논문AI추천

Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive reviewJong Man Kim, Sang Jin Kim대한간학회 · Clinical and Molecular Hepatology2022 · 제28권 제4호Criteria and prognostic models for patients with hepatocellular carcinoma undergoing liver transplantationChuan Shen, Jian-jun Zhang, Jie Cao, Jun Wang, Meng Sha, Qiang Xia, Seogsong Jeong, Xiao-ye Qu, Ying Tong, Zhi-feng Xi, Zhi-Hui Zou대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호Can hepatocellular carcinoma recurrence be prevented after liver transplantation?Jong Man Kim대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제4호Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation홍근, 김율희, 김향숙, 김혜령, 서경석, 이광웅, 이남준, 이병구, 이주연, 이혜숙, 최영록대한간학회 · Clinical and Molecular Hepatology2014 · 제20권 제2호Prognosis of Hepatocellular Carcinoma after Liver Transplantation: Comparative Analysis with Partial Hepatectomy서경석, 이경분, 이규호, 이남준, 장자준대한병리학회 · Journal of Pathology and Translational Medicine2017 · 제51권 제1호Solitary Extrahepatic Intraabdominal Metastasis from Hepatocellular Carcinoma after Liver Transplantation김경식, 김성훈, 김현기, 박영년, 최새별연세대학교의과대학 · Yonsei Medical Journal2011 · 제52권 제1호

이 간행물의 다른 논문 (10건)

Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virusJun Sik Yoon, 이민종, Yuri Cho, Sun Woong Kimpp. 17-30Current knowledge about biomarkers of acute kidney injury in liver cirrhosisYeon Seok Seo, Han Ah Leepp. 31-46Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?Seung Mi Lee, 김원pp. 47-49Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment권자영pp. 50-51Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomesGuy D Eslick, Martin Weltman, Hydar El Jamalypp. 52-66
원문 보기